YTHDC1 and neoplasm: These studies affirm that targeting YTHDF1/2 and YTHDC1/2 in human cancers can reactivate the anti‐tumour immune response and enhance the efficacy of ICI therapy, offering new avenues for targeted therapeutic approaches.